Literature DB >> 29684361

High Frequency of Ovarian Cyst Development in Vhl2B/+;Snf5+/- Mice.

Yasumichi Kuwahara1, Leslie M Kennedy1, Anthony N Karnezis2, E Lorena Mora-Blanco3, Arlin B Rogers4, Christopher D Fletcher5, David G Huntsman2, Charles W M Roberts3, W Kimryn Rathmell6, Bernard E Weissman7.   

Abstract

The new paradigm of mutations in chromatin-modifying genes as driver events in the development of cancers has proved challenging to resolve the complex influences over disease phenotypes. In particular, impaired activities of members of the SWI/SNF chromatin remodeling complex have appeared in an increasing variety of tumors. Mutations in SNF5, a member of this ubiquitously expressed complex, arise in almost all cases of malignant rhabdoid tumor in the absence of additional genetic alterations. Therefore, we studied how activation of additional oncogenic pathways might shift the phenotype of disease driven by SNF5 loss. With the use of a genetically engineered mouse model, we examined the effects of a hypomorphic Vhl2B allele on disease phenotype, with a modest up-regulation of the hypoxia response pathway. Snf5+/-;Vhl2B/+ mice did not demonstrate a substantial difference in overall survival or a change in malignant rhabdoid tumor development. However, a high percentage of female mice showed complex hemorrhagic ovarian cysts, a phenotype rarely found in either parental mouse strain. These lesions also showed mosaic expression of SNF5 by immunohistochemistry. Therefore, our studies implicate that modest changes in angiogenic regulation interact with perturbations of SWI/SNF complex activity to modulate disease phenotypes.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29684361      PMCID: PMC6024179          DOI: 10.1016/j.ajpath.2018.03.010

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.

Authors:  Lien N Hoang; Yow-Shan Lee; Anthony N Karnezis; Basile Tessier-Cloutier; Noorah Almandani; Mackenzie Coatham; C Blake Gilks; Robert A Soslow; Colin J R Stewart; Martin Köbel; Cheng-Han Lee
Journal:  Histopathology       Date:  2016-07-05       Impact factor: 5.087

2.  An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aromatase) gene.

Authors:  K L Britt; A E Drummond; V A Cox; M Dyson; N G Wreford; M E Jones; E R Simpson; J K Findlay
Journal:  Endocrinology       Date:  2000-07       Impact factor: 4.736

Review 3.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

4.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

5.  SRG3, a core component of mouse SWI/SNF complex, is essential for extra-embryonic vascular development.

Authors:  Daehee Han; Shin Jeon; Dong Hyun Sohn; Changjin Lee; Sangil Ahn; Won Kyu Kim; Heekyoung Chung; Rho Hyun Seong
Journal:  Dev Biol       Date:  2007-12-27       Impact factor: 3.582

6.  Two human homologues of Saccharomyces cerevisiae SWI2/SNF2 and Drosophila brahma are transcriptional coactivators cooperating with the estrogen receptor and the retinoic acid receptor.

Authors:  H Chiba; M Muramatsu; A Nomoto; H Kato
Journal:  Nucleic Acids Res       Date:  1994-05-25       Impact factor: 16.971

7.  Selective expression of KrasG12D in granulosa cells of the mouse ovary causes defects in follicle development and ovulation.

Authors:  Heng-Yu Fan; Masayuki Shimada; Zhilin Liu; Nicola Cahill; Noritaka Noma; Yun Wu; Jan Gossen; JoAnne S Richards
Journal:  Development       Date:  2008-06       Impact factor: 6.868

8.  Establishment and characterization of MRT cell lines from genetically engineered mouse models and the influence of genetic background on their development.

Authors:  Yasumichi Kuwahara; E Lorena Mora-Blanco; Fatima Banine; Arlin B Rogers; Christopher Fletcher; Larry S Sherman; Charles W M Roberts; Bernard E Weissman
Journal:  Int J Cancer       Date:  2012-12-27       Impact factor: 7.396

9.  VHL Type 2B gene mutation moderates HIF dosage in vitro and in vivo.

Authors:  C M Lee; M M Hickey; C A Sanford; C G McGuire; C L Cowey; M C Simon; W K Rathmell
Journal:  Oncogene       Date:  2009-03-02       Impact factor: 9.867

10.  Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis.

Authors:  Chengkai Dai; Luke Whitesell; Arlin B Rogers; Susan Lindquist
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.